AgomAb Therapeutics NV (AGMB)
NASDAQ: AGMB · Real-Time Price · USD
8.57
-0.48 (-5.30%)
Oct 26, 2026, 4:00 PM EDT - Market closed
AgomAb Therapeutics NV Employees
AgomAb Therapeutics NV had 62 employees as of December 31, 2025. The number of employees increased by 4 or 7.27% compared to the previous year. That makes AgomAb Therapeutics NV the 33,957th largest employer in the world and 4,503rd in the United States.
Employees
62
Change (1Y)
4
Growth (1Y)
7.27%
Revenue / Employee
n/a
Profits / Employee
-$1,503,706
Market Cap
422.06M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 62 | 4 | 7.27% |
| Dec 31, 2024 | 58 | 24 | 70.00% |
| Dec 31, 2023 | 34 | 33 | 3,300.00% |
| Dec 31, 2019 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| REGENXBIO | 371 |
| Phathom Pharmaceuticals | 371 |
| ProKidney | 231 |
| Allogene Therapeutics | 152 |
| MapLight Therapeutics | 133 |
| Eupraxia Pharmaceuticals | 49 |
| Surrozen | 44 |
| DiaMedica Therapeutics | 35 |
AGMB News
- 13 days ago - Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease - GlobeNewsWire
- 25 days ago - AgomAb Therapeutics NV Transcript: Study result - Transcripts
- 25 days ago - AgomAb Therapeutics NV Press release: Study result - Filings
- 25 days ago - AgomAb Therapeutics NV Slides: Study result - Filings
- 25 days ago - Agomab’s ontunisertib shows positive results in Crohn’s Disease study - TheFly
- 25 days ago - Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease - GlobeNewsWire
- 6 weeks ago - Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study - GlobeNewsWire
- 6 weeks ago - Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors - GlobeNewsWire